Healthcare / Health Information ServicesAthens
$9.10
+0.70 (+8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-26411.24 · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
67/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
16.0x
↓EV/EBITDA
10.8x
↓ROE
32.7%
↑Gross Margin
55.2%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+50.2%
FCF CAGR
—
FCF margin
-1.2%
FCF / Net income
-0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.2M · net income $593133.8 · FCF $-26411.2
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.2M | $2.2M | $1.1M | $697228.63 | $638443.63 |
| Net Income | $593133.79 | $593133.79 | $-30359.16 | $123941.52 | $-100833.60 |
| EBITDA | $820758.08 | $820758.08 | $7529.64 | $188809.47 | $-67465.55 |
| EPS | — | — | — | 0.14 | -0.12 |
| Gross Margin | 55.2% | 55.2% | 33.5% | 73.2% | 64.6% |
| Operating Margin | 35.4% | 35.4% | -1.7% | 22.1% | -5.5% |
| Net Margin | 27.4% | 27.4% | -2.8% | 17.8% | -15.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.03 | 0.05 | 0.11 |
| Current Ratio | 2.59 | 2.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26411.24 | $-26411.24 | $-27821.71 | $144533.07 | $-22874.11 |
| Returns | |||||
| ROE | 32.7% | 32.7% | -4.1% | 16.2% | -15.8% |
| Valuation | |||||
| P/E | 15.96 | 15.96 | — | 18.95 | — |
| EV/EBITDA | 10.83 | 10.83 | 328.36 | 12.65 | — |
| P/B | 5.25 | 5.25 | 3.57 | 3.35 | 4.44 |
| Growth & Yield | |||||
| Revenue Growth | 97.4% | 97.4% | 57.1% | 9.2% | — |
| EPS Growth | — | — | — | 223.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+96.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+96.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.